Clinical Trials Logo
  1. Home
  2. Endometrial Thickness
  3. NCT04619914

the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

Pregnancy Rate Clinical Trial

Official title:
Comparison of the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women With Polycystic Ovarian Syndrome

Clinical Trial Summary

The present randomized double blind study has been carried out in Gynecology and Obstetrics Department, Faculty of Medicine, Zagazig university on 70 women were previously received clomiphene citrate alone as management of infertile anovulatory PCOS women, but giving improper endometrial thickness < 7mm during the period from March 2019 to September 2019

Clinical Trial Description

Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorder in infertile women. Infertility affects 40% of women with PCOS. Understanding the main causes of infertility and selecting an appropriate treatment plan is a diagnostic and therapeutic priority The aim of this work was to compare the effect of Clomiphene citrate plus Estradiol Valerate versus Letrozole on endometrial thickness and pregnancy rate in infertile PCOS women underwent ovulation induction The study was designed as a randomized double blind study using a computer-generated randomization list and sequentially numbered opaque sealed envelopes, each containing the allocation information written on a card. Envelopes were opened sequentially by a study nurse to allocate patients to the assigned group. These patients were divided into two groups: 1. Group A (clomiphene citrate & estradiol group): included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14. 2. Group B (Letrozole group): included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04619914
Study type Interventional
Source Zagazig University
Contact
Status Completed
Phase N/A
Start date March 1, 2019
Completion date August 10, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT05721495 - Deferred Embryo Transfer in an In Vitro Program With Single Embryo Transfer Policy N/A
Not yet recruiting NCT02099916 - Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF Phase 2/Phase 3
Not yet recruiting NCT05173038 - Second Ejaculate and IUI
Completed NCT02809989 - A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.
Enrolling by invitation NCT03579550 - Hysteroscopic Metroplasty in Unexplained Infertile Women With Dysmorphic Uterus N/A
Recruiting NCT04389203 - Pregnancy Rate After Unilateral Tubal Disconnection N/A
Not yet recruiting NCT00542126 - Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles N/A
Not yet recruiting NCT05467852 - Didroxyprogesterone Promotes Natural Pregnancy in Infertile Patients With Endometriosis Phase 3
Recruiting NCT01933126 - Intrauterine Injection of HCG and Implantation Rate N/A
Recruiting NCT01933009 - The Effect of GnRH Administration During Luteal Support in Frozen-thawed Transfer Cycles N/A
Completed NCT04500743 - Role of Suppression of Endometriosis With Progestins Before IVF-ET N/A